All News

Investigators will present full results from the phase 3 GMMG-HD7 trial at a future medical meeting.

Data from the phase 3 MELATORCH study support the supplemental new drug application for frontline toripalimab in unresectable or metastatic melanoma.

Developers anticipate launching a first-in-human phase 1 study assessing ziftomenib/imatinib for those with advanced GISTs in early 2025.

Targeting multiple survival pathways simultaneously with ViPOR may be effective in specific molecular subtypes of relapsed/refractory DLBCL.

A recent study, published in Blood Advances, has identified that pre-HSCT conditioning induces the extracellular release of damaged mitochondria, exacerbating GVHD.

Enrollment will soon begin for the dose-expansion portion of the ongoing phase 1 trial assessing EO-3021 in CLDN18.2-positive tumors.

A recent study, published in Cell, has identified the circadian rhythm of TILs as a key determinant in the efficacy of immunotherapy treatments such as CAR T-cell therapy and immune checkpoint blockade.

Investigators are on track to launch part 2 of the phase 1 Deltacel-01 trial in September 2024.

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Reduction of long-term survival following CAR T-cell therapy associated with late infections and SMN development was observed, especially in elderly patients.

Adding metastasis-free directed radiation to chemotherapy more than tripled progression-free survival vs chemotherapy alone in the EXTEND trial.

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

The overall survival data in the phase 3 KeyVibe-008 trial met the prespecified futility criteria.

Retrospective analysis found that cryoablation was associated with infrequent AEs and low recurrence rates among patients with breast cancer.

FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.

The combination therapy was well tolerated and had a safety profile consistent with pembrolizumab monotherapy, while no new safety concerns were identified.

After a complete response letter and a subsequent biologics license application resubmission, denileukin diftitox has been approved by the FDA.

A holistic integration of time series and static data present in the learning approach can lead to improved understanding of breast cancer outcomes.

The SeCore CDx HLA A Sequencing System may help identify patients with advanced synovial sarcoma who are suitable to receive afami-cel.

Results from the LUMINOSITY trial show an enriched overall response rate for telisotuzumab vedotin among patients with c-Met high overexpressing tumors.

Combining evorpacept with trastuzumab, ramucirumab, and paclitaxel appeared to be well tolerated among patients enrolled on the phase 2 ASPEN-06 trial.

Phase 3 data from the INDIGO trial support the FDA approval of vorasidenib for select patients with grade 2 astrocytoma or oligodendroglioma.